Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Armand

Showing results (201-210 of 240) with videos related to

Pageof 24
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyA Italiano, C Massard, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinomaP Rougier, J J Zarba, M Ducreux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancerK Fizazi, M Ducreux, P Ruffié, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal typeA Hasbini, R Mahjoubi, A Fandi, et al.
Bone Marrow Transplantation|February 16, 2010
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapyP Armand, H T Kim, E Mayer, et al.
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative GroupJ H Schornagel, J Verweij, P H de Mulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumorsC Couteau, M L Risse, M Ducreux, et al.
Cancer|January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesisG Schwartsmann, E Bork, J B Vermorken, et al.
Pageof 24

Showing results (201-210 of 240) with videos related to

Sort By:
Pageof 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyA Italiano, C Massard, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinomaP Rougier, J J Zarba, M Ducreux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancerK Fizazi, M Ducreux, P Ruffié, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal typeA Hasbini, R Mahjoubi, A Fandi, et al.
Bone Marrow Transplantation|February 16, 2010
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapyP Armand, H T Kim, E Mayer, et al.
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative GroupJ H Schornagel, J Verweij, P H de Mulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumorsC Couteau, M L Risse, M Ducreux, et al.
Cancer|January 15, 1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesisG Schwartsmann, E Bork, J B Vermorken, et al.
Pageof 24